enVVeno Medical Corporation
NVNOHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeenVVeno Medical Corporation enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the. With a market capitalization of $6.8M, it sits in micro-cap territory. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency.
Market Cap
$6.8M
Beta
1.09
P/E (TTM)
—
P/E (Fwd)
-1.63
EPS (TTM)
$-28.71
EPS (Fwd)
$-6.22
ROE
-60.7%
ROA
-37.5%
Cash
$24.9M
Total Debt
$603,000
Free CF
-$8.4M
52W Change
-94.0%
Annual Financials
Cash vs Debt
Where NVNO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NVNO finished 0.73% below its 150-day moving average ($10.98) and 22.42% below its 200-day moving average ($14.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVNO overbought or oversold?
At the July 15, 2026 close, NVNO's RSI(14) was 63.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $24.9M in cash and $603K in debt, NVNO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$8.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -60.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, NVNO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for enVVeno Medical Corporation and its sector.